156 related articles for article (PubMed ID: 35323336)
1. The OncoSim-Breast Cancer Microsimulation Model.
Yong JHE; Nadeau C; Flanagan WM; Coldman AJ; Asakawa K; Garner R; Fitzgerald N; Yaffe MJ; Miller AB
Curr Oncol; 2022 Mar; 29(3):1619-1633. PubMed ID: 35323336
[TBL] [Abstract][Full Text] [Related]
2. The OncoSim model: development and use for better decision-making in Canadian cancer control.
Gauvreau CL; Fitzgerald NR; Memon S; Flanagan WM; Nadeau C; Asakawa K; Garner R; Miller AB; Evans WK; Popadiuk CM; Wolfson M; Coldman AJ
Curr Oncol; 2017 Dec; 24(6):401-406. PubMed ID: 29270052
[TBL] [Abstract][Full Text] [Related]
3. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
4. Long-term projections of cancer incidence and mortality in Canada: The OncoSim All Cancers Model.
Ruan Y; Poirier A; Yong J; Garner R; Sun Z; Than J; Brenner DR
Prev Med; 2023 Mar; 168():107425. PubMed ID: 36681276
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
[TBL] [Abstract][Full Text] [Related]
6. Effect of Breast Screening Regimen on Breast Cancer Outcomes: A Modeling Study.
Yaffe MJ; Mainprize JG
Curr Oncol; 2023 Oct; 30(11):9475-9483. PubMed ID: 37999106
[TBL] [Abstract][Full Text] [Related]
7. Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model.
Yaffe MJ; Mittmann N; Lee P; Tosteson AN; Trentham-Dietz A; Alagoz O; Stout NK
Health Rep; 2015 Dec; 26(12):3-8. PubMed ID: 26676233
[TBL] [Abstract][Full Text] [Related]
8. The Economic Burden of Cancer in Canada from a Societal Perspective.
Garaszczuk R; Yong JHE; Sun Z; de Oliveira C
Curr Oncol; 2022 Apr; 29(4):2735-2748. PubMed ID: 35448197
[TBL] [Abstract][Full Text] [Related]
9. Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees.
Fenton JJ; Xing G; Elmore JG; Bang H; Chen SL; Lindfors KK; Baldwin LM
Ann Intern Med; 2013 Apr; 158(8):580-7. PubMed ID: 23588746
[TBL] [Abstract][Full Text] [Related]
10. Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study.
de Glas NA; de Craen AJ; Bastiaannet E; Op 't Land EG; Kiderlen M; van de Water W; Siesling S; Portielje JE; Schuttevaer HM; de Bock GT; van de Velde CJ; Liefers GJ
BMJ; 2014 Sep; 349():g5410. PubMed ID: 25224469
[TBL] [Abstract][Full Text] [Related]
11. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
[TBL] [Abstract][Full Text] [Related]
12. Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects.
Beckmann K; Duffy SW; Lynch J; Hiller J; Farshid G; Roder D
J Med Screen; 2015 Sep; 22(3):127-35. PubMed ID: 25896926
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program.
Hofvind S; Lee CI; Elmore JG
Breast Cancer Res Treat; 2012 Aug; 135(1):291-9. PubMed ID: 22833199
[TBL] [Abstract][Full Text] [Related]
14. Participatory simulation modeling to inform colorectal cancer screening in a complex remote northern health system: Canada's Northwest Territories.
Smith HA; Yong JHE; Kandola K; Boushey R; Kuziemsky C
Int J Med Inform; 2021 Jun; 150():104455. PubMed ID: 33857774
[TBL] [Abstract][Full Text] [Related]
15. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
16. Screening detects a myriad of breast disease - refining practice will increase effectiveness and reduce harm.
Lyburn ID; Pinder SE
Br J Radiol; 2020 Nov; 93(1115):20200135. PubMed ID: 32816520
[TBL] [Abstract][Full Text] [Related]
17. Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening.
Luke C; Priest K; Roder D
Asian Pac J Cancer Prev; 2006; 7(1):69-74. PubMed ID: 16629519
[TBL] [Abstract][Full Text] [Related]
18. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
19. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
20. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
